JP2005536442A5 - - Google Patents

Download PDF

Info

Publication number
JP2005536442A5
JP2005536442A5 JP2003533863A JP2003533863A JP2005536442A5 JP 2005536442 A5 JP2005536442 A5 JP 2005536442A5 JP 2003533863 A JP2003533863 A JP 2003533863A JP 2003533863 A JP2003533863 A JP 2003533863A JP 2005536442 A5 JP2005536442 A5 JP 2005536442A5
Authority
JP
Japan
Prior art keywords
insulin
liposome
solution
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003533863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536442A (ja
Filing date
Publication date
Priority claimed from US09/975,752 external-priority patent/US20030068361A1/en
Application filed filed Critical
Publication of JP2005536442A publication Critical patent/JP2005536442A/ja
Publication of JP2005536442A5 publication Critical patent/JP2005536442A5/ja
Pending legal-status Critical Current

Links

JP2003533863A 2001-10-09 2002-10-07 リポソーム封入インスリン製剤 Pending JP2005536442A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/975,752 US20030068361A1 (en) 2001-10-09 2001-10-09 Liposome-encapsulated insulin formulations
PCT/US2002/032201 WO2003030829A2 (en) 2001-10-09 2002-10-07 Liposome-encapsulated insulin formulations

Publications (2)

Publication Number Publication Date
JP2005536442A JP2005536442A (ja) 2005-12-02
JP2005536442A5 true JP2005536442A5 (cg-RX-API-DMAC7.html) 2006-01-19

Family

ID=25523349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003533863A Pending JP2005536442A (ja) 2001-10-09 2002-10-07 リポソーム封入インスリン製剤

Country Status (6)

Country Link
US (2) US20030068361A1 (cg-RX-API-DMAC7.html)
EP (1) EP1434601A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005536442A (cg-RX-API-DMAC7.html)
AU (1) AU2002330273A1 (cg-RX-API-DMAC7.html)
CA (1) CA2461048A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003030829A2 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642524B (zh) * 2002-03-12 2011-05-18 微计量治疗公司 通过吸入部位特异性递送联合施用的药物
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US20060135906A1 (en) * 2004-11-16 2006-06-22 Akihiko Matsumura Iontophoretic device and method for administering immune response-enhancing agents and compositions
IL174387A0 (en) * 2005-03-31 2008-01-20 Dexcel Pharma Technologies Ltd A solid composition for intra-oral delivery of insulin
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
WO2007041322A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
EP1965856A2 (en) 2005-12-30 2008-09-10 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
WO2008087803A1 (ja) * 2007-01-16 2008-07-24 Hokkaido University 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
NZ582049A (en) * 2007-05-18 2012-12-21 Tti Ellebeau Inc Transdermal delivery devices assuring an improved release of an active principle through a biological interface
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP2012501801A (ja) * 2008-09-10 2012-01-26 トランスキュー リミテッド ヒドロキシプロピルセルロース(hpc)をベースにした粘性液体を多孔質基材に薬剤投与する装置および方法、例えば連続ウェブをベースにしたプロセス
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
JP5638204B2 (ja) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 経口投与用リポソーム製剤およびその製造方法
CN102665807A (zh) 2010-01-05 2012-09-12 微剂量治疗技术公司 吸入设备和方法
US10525214B2 (en) 2010-01-12 2020-01-07 Dance Biopharm Inc. Preservative-free single dose inhaler system
US8950394B2 (en) 2010-01-12 2015-02-10 Dance Biopharm Inc. Preservative-free single dose inhaler systems
US9545488B2 (en) 2010-01-12 2017-01-17 Dance Biopharm Inc. Preservative-free single dose inhaler systems
US20130269684A1 (en) 2012-04-16 2013-10-17 Dance Pharmaceuticals, Inc. Methods and systems for supplying aerosolization devices with liquid medicaments
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US20150072929A1 (en) * 2011-02-01 2015-03-12 Artur Martynov Pharmaceutical composition comprising a mixture of carboxylated oligopeptides
EP2756842A1 (en) * 2013-01-18 2014-07-23 Nano and Advanced Materials Institute Limited Synthesis and use of Polyhydroxyalkanoate (PHA) Nanocapsules as a protein carrier
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10471222B2 (en) 2014-07-01 2019-11-12 Dance Biopharm Inc. Aerosolization system with flow restrictor and feedback device
US10857313B2 (en) 2014-07-01 2020-12-08 Aerami Therapeutics, Inc. Liquid nebulization systems and methods
US11273271B2 (en) 2014-07-01 2022-03-15 Aerami Therapeutics, Inc. Aerosolization system with flow restrictor and feedback device
EP3261648B1 (en) 2015-02-25 2023-12-06 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
KR101764388B1 (ko) * 2016-03-17 2017-08-02 한국화학연구원 피하주사용 인슐린 함유 리포솜 조성물
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
EP4061408A4 (en) * 2019-11-22 2024-04-10 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS OF USE IN TYPE 1 DIABETES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (cg-RX-API-DMAC7.html) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
AR012894A1 (es) * 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.

Similar Documents

Publication Publication Date Title
CN101917979B (zh) 包含外壁壳的制剂
Morales et al. Novel strategies for the buccal delivery of macromolecules
JP6751424B2 (ja) ダイズホスファチジルセリンで作られたコクリエート
US5762904A (en) Oral delivery of vaccines using polymerized liposomes
CA2642479A1 (en) A gastro-retentive system for the delivery of macromolecules
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2005028516A3 (en) Albumin-binding derivatives of therapeutic peptides
US20030166508A1 (en) Biologically active oral preparation that can be site-specific released in colon
WO2005117843A3 (en) Sustained release preparations
JP2002512947A5 (cg-RX-API-DMAC7.html)
JP2012144577A5 (cg-RX-API-DMAC7.html)
JP2007522094A5 (cg-RX-API-DMAC7.html)
CA3082201C (en) Pouch-type orally dissolving films with high active ingredient concentration
WO2003070173A3 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
CA2567857A1 (en) Irinotecan liposome formulation
KR20080100376A (ko) 친수성 단백질에 기초한 활성제-농축된 나노입자
WO2004098537A3 (en) Activation agents on the surface of encapsulation vesicles
Vanea et al. XPS and Raman study of zinc containing silica microparticles loaded with insulin
ATE422356T1 (de) Pharmazeutische zubereitungen
WO2006007354A3 (en) A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
Dos Santos et al. Nanoparticles functionalized with venom-derived peptides and toxins for pharmaceutical applications
Porte et al. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity
WO2003018064A3 (en) Lipophilic drug compositions
EP1753410A1 (en) Multi-layered controlled-release methylphenidate pellet
US20030219473A1 (en) Cochleates made with purified soy phosphatidylserine